CD151 inhibits brain metastasis of non-small cell lung cancer by regulating epithelial-mesenchymal transition and stemness pathways

Shuai WANG; Shiheng ZHANG; Zhimin ZHANG; Zhenzhou YANG

doi:10.16016/j.1000-5404.201712264

您当前的位置：

首页 >

文章列表页 >

CD151 inhibits brain metastasis of non-small cell lung cancer by regulating epithelial-mesenchymal transition and stemness pathways

Basic Medicine | 更新时间：2026-01-09

- CD151 inhibits brain metastasis of non-small cell lung cancer by regulating epithelial-mesenchymal transition and stemness pathways
- Journal of Third Military Medical University Vol. 40, Issue 10, Pages: 862-867(2018)
- 作者机构：
  
  400042 重庆，陆军军医大学(第三军医大学)第三附属医院(野战外科研究所)肿瘤中心
- 作者简介：
- 基金信息：
  
  the Project of Basic and Frontier Technology Research of Chongqing(CSTC2015jcyjBX0084)
- DOI：10.16016/j.1000-5404.201712264
  CLC： R73.37;R730.23;R734.2
- Received：27 December 2017，
  
  Revised：2018-02-21，
  
  Published：30 May 2018
- 稿件说明：
移动端阅览
Shuai WANG, Shiheng ZHANG, Zhimin ZHANG, et al. CD151 inhibits brain metastasis of non-small cell lung cancer by regulating epithelial-mesenchymal transition and stemness pathways[J]. Journal of Third Military Medical University, 2018, 40(10): 862-867.
DOI：

Shuai WANG, Shiheng ZHANG, Zhimin ZHANG, et al. CD151 inhibits brain metastasis of non-small cell lung cancer by regulating epithelial-mesenchymal transition and stemness pathways[J]. Journal of Third Military Medical University, 2018, 40(10): 862-867. DOI： 10.16016/j.1000-5404.201712264.

摘要

目的

探讨四跨膜蛋白CD151在肺癌脑转移中的预测作用及相关分子通路机制。

方法

收集2010年12月至2015年6月本中心160例非小细胞肺癌(non-small cell lung cancer

NSCLC)患者临床资料，其中脑转移患者88例，无脑转移患者72例，采用免疫组织化学方法检测CD151在肺癌组织的表达，并运用Spearman分析CD151表达与脑转移相关性。再选择人NSCLC细胞株HCC827，应用siRNA干扰、Western blot、划痕和Transwell实验检测敲低CD151表达对细胞增殖、迁移状况以及上皮间质转化(EMT)、干性通路相关蛋白表达的影响。

结果

相对于无脑转移患者，NSCLC脑转移患者肺癌组织CD151表达显著增加(

=0.012)，Spearman分析表明CD151高表达与脑转移呈正相关(

=0.478

=0.004)。通过siRNA敲低CD151可上调Ecadherin表达，并下调Vimentin、SOX2、CD44和CD133表达，同时降低HCC827细胞增殖(

=0.026)与迁移能力(

=0.032)。

结论

CD151可能通过调控EMT、干性通路相关蛋白表达影响NSCLC细胞的增殖、迁移，CD151可能是NSCLC脑转移的潜在预测因子。

Abstract

Objective

To investigate the value of CD151 for predicting brain metastasis of lung cancer and explore its role in promoting lung cancer metastasis and the associated signaling pathways.

Methods

A total of 160 patients with non-small cell lung cancer (NSCLC) admitted in our center between December

2010 and June

2015 were enrolled in this study

including 88 patients with and 72 without brain metastases. CD151 expression in the lung cancer tissues was examined using immunohistochemistry and its correlation with brain metastasis was analyzed. In the

in vitro

experiment with human NS

CLC cell line (HCC827 cells)

RNA interference technique

scratch-wound assay

Transwell assay and Western blotting were used to clarify the role of CD151 in regulating cell proliferation

migration

epithelial-mesenchymal transition

and expressions of proteins in the stemness pathways.

Results

Compared with those without brain metastasis

the patients with brain metastasis of NSCLC showed significantly up-regulated CD151 expression in the lung cancer tissues (

=0.012). Spearman correlation analysis showed that a high expression of CD151 was positively correlated with brain metastasis of NSCLC (

=0.478

=0.004). HCC827 cells with CD151 knockdown mediated by a small interfering RNA showed obviously suppressed cell proliferation (

=0.026) and metastasis (

=0.032)

up-regulated expression of E-cadherin and down-regulated expression of vimentin

SOX2

CD44 and CD133.

Conclusion

CD151 promotes the proliferation and migration of NSCLC cells possibly by regulating the protein expression associated with epithelial-mesenchymal transition and stemness pathways

suggesting its value as a potential biomarker for predicting brain metastases of lung cancer.

关键词

Keywords

references

CHEN W, ZHENG R, BAADE P D. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.

JEMAL A, CENTER M M, DESANTISC. Global patterns of cancer incidence and mortality rates and trends[J]. Cancer Epidemiol Biomarkers Prev, 2010, 19(8): 1893-1907. DOI: 10.1158/1055-9965.

BROWN T, PILKINGTON G, BAGUST A, et al . Clinical effectiveness and cost-effectiveness of fi rst-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation[J ] . Health Technol Assess, 2013, 17(31): 1-278. DOI: 10.3310/hta17310.

SPIRO S G, TANNER N T, SILVESTRI G A, et al .Lungcancer: progress in diagnosis, staging andtherapy[J ] . Respirology, 2010, 15(1): 44-50. DOI: 10.1111/j.1440-1843.2009.01674.x.

KAWAHARA M, ATAGI S, KOMUTA K, et al . Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small cell lung cancer[J ] . Anticancer Res, 2013, 33(10): 4631-4637. DOI: 0.1371/journal.pone.0111475.

TATAR Z, THIVAT E, PLANCHAT E, et al . Temozolomide and unusual indications: review of literature[J ] . Cancer Treat Rev, 2013, 39(2): 125-135. DOI: 10.1016/j.ctrv.2012.06.002.

LIU WJ, ZENG XT, QIN HF, et al . Whole brain radiotherapy plus chemotherapy in the treatment of brain metastases from lung cancer: a meta-analysis of 19 randomized controlled trails[J ] . Asian Pac J Cancer Prev, 2012, 13(7): 3253-3258. DOI: 10.7314/APJCP.2012.13.7.3253.

WANG H X, LIQ, SHARMAC, et al . Tetraspanin protein contributions to cancer[J ] . Biochem Soc Trans, 2011, 39(2): 547-552. DOI: 10.1042/BST0390547.

GHELDOF A, BERX G. Cadherins and epithelial-to-mesenchymaltransition[J]. Prog Mol Biol Transl Sci. 2013, 116: 317-336. DOI: 10.1016/B978-0-12-394311-8.00014-5.

THIERY J P, ACLOQUE H, HUANG RY J, et al . Epithelial-mesenchymal transitions in development and disease[J ] . Cell, 2009, 139(5): 871-890. DOI: 10.1016/j.cell.2009.11.007.

MEDEMA J P. Cancer stem cells: the challenges ahead[J]. Nat Cell Biol, 2013, 15(4): 338-344. DOI: 10.1038/ncb2717.

李科, 洪志鹏, 沈丽达, 等. CD151及整合素α整合素蛋白在非小细胞肺癌中的表达及意义[J].中国全科医学, 2014, 17(5): 531-535. DOI: 10.3969/j.issn.1007-9572.

LI K, HONG Z P, SHEN L D, et al . CD151 and integrin α3β1 expression in non-small cell lung cancer[J ] . Chin Gen Prac, 2014, 17(5): 531-535. DOI: 10.3969/j.issn.1007-9572.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Integrative model combining deep learning, clinical and radiomic features enhances EGFR mutation prediction in non-small cell lung cancer

Preparation of doxorubicin-loaded polyphyllin H liposomes and synergistic anti-tumor activity against non-small cell lung cancer in vitro

Development of a postoperative recurrence prediction model for stage Ⅰ non-small cell lung cancer patients using multimodal data based on machine learning

Progress and prospect of epidermal growth factor receptor tyrosine kinase inhibitor in treatment of non-small cell lung cancer

Correlation of serum tumor markers and incidence of driver gene mutations in non-small cell lung cancer

Related Author

YANG Taotao

CHEN Wei

CHEN Cancan

YAN Wanying

WANG Dawei

XIONG Kunlin

SUN Zhiyuan

WANG Xianqi

Related Institution

Department of Diagnostic Radiology， Eastern Theatre General Hospital

Department of Radiology， Daping Hospital， Army Medical University

Department of Radiology，First Affiliated Hospital， Army Medical University （Third Military Medical University）

Infervision Medical Technology Co.， Ltd

Department of Medical Service,No. Hospital of Joint Logistics Support Force

⁰